Several companies, including Boston Scientific and Corindus Vascular Robotics, have released details of their presentations at the upcoming 2019 Transcatheter Cardiovascular Therapeutics (TCT) meeting (25–29 September, San Francisco, USA).
- 25 September (Wednesday); 4.35pm; Room 203
Abstract: Hypertension and heart failure therapies (session II) heart failure therapies, TCT 88—six-month outcomes of an early feasibility study of the AccuCinch left ventricular repair system in patients with heart failure and functional mitral regurgitation.
- 27 September (Friday); 5.24pm; Room 155/157
Transcatheter mitral valve repair—beyond the MitraClip (session III)—emerging TMVR devices; part 2; annuloplasty and others, basal ventriculoplasty: ancora device description results and ongoing studies
- 28 September (Saturday); 5.30pm; Room 156/158
Interventional heart failure and haemodynamic support—chronic therapies–device-based therapies for chronic heart failure, ventricular reshaping for HF: ANCORA
- 25 September (Wednesday); 3.45pm; room 209–210Abstract: Lotus aortic valve system—mid-term outcomes after transcatheter aortic valve replacement with a mechanically-expanded versus self-expandable valve: three-year results from the REPRISE III randomised trial.
- 26 September (Thursday); 12.15pm; Main Arena 1
Late-breaking trial: Synergy BP stent—primary outcomes of the evolve short DAPT study evaluating 3-month dual antiplatelet therapy in high bleeding risk patients treated with the synergy everolimus-eluting, bioabsorbable polymer-coated coronary stent.
Corindus Vascular Robotics
- 27 September (Friday); 6.45–7.45am; Room 216
Breakfast symposium—Transforming robotics into an advanced clinical tool through automation and remote capabilities.
- 26 September (Thursday); breakfast symposium—Supersaturated oxygen in STEMI to reduce infarct size–a new FDA approved therapy.
- 26 September (Thursday); poster—one year outcomes of supersaturated oxygen therapy in acute anterior myocardial infarction (the IC HOT Study); 2pm; Hall D.
- 26 September (Thursday); SSO2 Therapy: STEMI Case Studies; 2pm; Hall D.
- 26 September (Thursday); infarct size reduction—from the first FDA approved therapy SSO2 to novel approach; 4.35pm; Room 151/153.